ERBB2 and breast carcinoma: In recent years, the introduction of antibody–drug conjugates, such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), has further improved treatment efficacy, thus making HER2-positive breast cancer the subtype with the most notable therapeutic advances [4, 5].